We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.
Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.
Penny Stock of the Day: Anavex Life Sciences Corp. (NASDAQ: AVXL)
Today’s penny stock pick is the biopharmaceutical company, Anavex Life Sciences Corp. (NASDAQ: AVXL).
Anavex Life Sciences Corp. engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer’s disease; a Phase 2 proof-of-concept study in Parkinson’s disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors.
The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies.
Website: https://www.anavex.com/
Latest 10-K report: https://www.sec.gov/cgi-bin/viewer?action=view&cik=1314052&accession_number=0001731122-25-001596&xbrl_type=v
Analyst Consensus: As per TipRanks Analytics, based on 1 Wall Street analyst offering 12-month price targets for AVXL in the last 3 months, the stock has an average price target of $20.00, which is nearly 351% upside from current levels.
Analysts | Source: TipRanks.com
Potential Catalysts / Reasons for the Hype:
- The company recently presented new data at the AD/PD conference for its lead Alzheimer’s drug, blarcamesine. The data showed a consistent correlation between the drug preserving brain volume and improving clinical outcomes
- Unlike currently approved Alzheimer’s treatments that require cumbersome and expensive intravenous (IV) infusions, blarcamesine is a once-daily oral pill. If approved, the convenience factor for patients and caregivers would be a massive competitive moat.
- The company reported having $131.7 million in cash at the end of 2025. They have zero debt and estimate a cash runway of over 3 years, which significantly lowers the immediate risk of surprise stock dilution.
- The company recently had a successful Type C meeting with the FDA. The FDA appeared open to Anavex submitting a New Drug Application (NDA) based on their existing Phase IIb/III data, which is a major step forward.
- Upcoming triggers include top-line data from their Phase 2 clinical trial of ANAVEX 3-71 for Schizophrenia, and the initiation of new trials for Parkinson’s and Fragile X syndrome.
On analyzing the company’s stock charts, there seem to be multiple bullish indications…
Bullish Indications
#1 Symmetrical Triangle Pattern: The daily chart shows that the stock has currently formed a symmetrical triangle pattern, which is marked as purple color lines. A symmetrical triangle pattern represents a period of consolidation before the price breaks out. This is typically formed when there is indecision in the price movements and uncertainty among the buyers and sellers. Once a breakout from the upper trend line occurs, it usually signifies the start of a new bullish trend.
AVXL – Daily Chart
#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.
#3 Bullish Stoch: The %K line of the stochastic is above the %D line, and has also moved higher from oversold levels, indicating possible bullishness.
#4 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink dotted line. This looks like a good area for the stock to move higher.
AVXL – Weekly Chart
#5 MACD above Signal Line: In the weekly chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.
Recommended Trade (based on the charts)
Buy Levels: If you want to get in on this trade, the ideal buy level for AVXL is above the price of $4.80.
Target Prices: Our first target is $6.00. If it closes above that level, the second target price is $7.00.
Stop Loss: To limit risk, place a stop loss at $4.10. Note that the stop loss is on a closing basis.
Our target potential upside is 43% to 90%.
For a risk of $0.70, our first target reward is $1.20, and the second target reward is $2.20. This is a nearly 1:2 and 1:3 risk-reward trade.
In other words, this trade offers 2x to 3x more potential upside than downside.
Potential Risks / Red Flags:
- The company has a history of net losses.
AVXL – Consolidated Statements of Operations
- The European Medicines Agency (EMA) had issued a negative opinion on the marketing authorization for blarcamesine. Anavex is currently undergoing a re-examination process, but overcoming a negative EMA opinion is usually considered difficult.
- The company has zero revenue and competition from approved AD therapies (Leqembi, Kisunla) that are injectables.
- Despite being a loss-making company, the executives are being paid significant compensation.
AVXL – Executive Compensation
- Historically, the broader biotech market and some analysts have been highly skeptical of Anavex’s trial designs, specifically how they analyze their data and endpoints.
As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!
Happy Trading!
Trades of the Day Research Team
READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.
Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.
To carry out Trump's Executive Order #14196 initiative, the administration will have to partner with a handful of U.S. companies that control the "reserve accounts" sitting on trillions of dollars' worth of untapped natural resources. I've spent months digging into this – and I've identified three companies that have already been granted "emergency status" and fast-track approvals. I believe their shares could skyrocket once new capital starts moving into the sector. See the three stocks that I expect to be the biggest winners as this plan rolls.